Adaptimmune Therapeutics plc (ADAP): Price and Financial Metrics


Adaptimmune Therapeutics plc (ADAP): $2.17

-0.02 (-0.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADAP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ADAP POWR Grades

  • ADAP scores best on the Sentiment dimension, with a Sentiment rank ahead of 96.27% of US stocks.
  • ADAP's strongest trending metric is Value; it's been moving down over the last 179 days.
  • ADAP's current lowest rank is in the Momentum metric (where it is better than 4.51% of US stocks).

ADAP Stock Summary

  • ADAPTIMMUNE THERAPEUTICS PLC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 14.87% of US listed stocks.
  • ADAP's price/sales ratio is 19.75; that's higher than the P/S ratio of 94.31% of US stocks.
  • As for revenue growth, note that ADAP's revenue has grown 181.31% over the past 12 months; that beats the revenue growth of 95.44% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ADAPTIMMUNE THERAPEUTICS PLC are RXRX, CRIS, TGTX, CRBU, and VSTM.
  • ADAP's SEC filings can be seen here. And to visit ADAPTIMMUNE THERAPEUTICS PLC's official web site, go to www.adaptimmune.com.

ADAP Valuation Summary

  • In comparison to the median Healthcare stock, ADAP's EV/EBIT ratio is 119.77% lower, now standing at -1.7.
  • ADAP's EV/EBIT ratio has moved up 4.8 over the prior 81 months.

Below are key valuation metrics over time for ADAP.

Stock Date P/S P/B P/E EV/EBIT
ADAP 2022-11-25 20.6 3.2 -2.1 -1.7
ADAP 2022-11-23 20.8 3.2 -2.1 -1.8
ADAP 2022-11-22 22.8 3.5 -2.3 -2.0
ADAP 2022-11-21 23.6 3.7 -2.4 -2.1
ADAP 2022-11-18 22.1 3.4 -2.2 -1.9
ADAP 2022-11-17 22.0 3.4 -2.2 -1.9

ADAP Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at 104.82%.
  • Its year over year net cashflow from operations growth rate is now at 102.45%.
  • The 4 year net income to common stockholders growth rate now stands at -92.68%.
ADAP's revenue has moved up $16,415,000 over the prior 33 months.

The table below shows ADAP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 17.537 -9.883 -175.064
2022-06-30 11.733 -6.924 -176.044
2022-03-31 9.29 2.868 -170.592
2021-12-31 6.149 10.729 -158.09
2021-09-30 6.234 -152.415 -155.845
2021-06-30 6.224 -123.532 -148.876

ADAP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADAP has a Quality Grade of C, ranking ahead of 58.13% of graded US stocks.
  • ADAP's asset turnover comes in at 0.016 -- ranking 378th of 682 Pharmaceutical Products stocks.
  • CALA, ACOR, and INSM are the stocks whose asset turnover ratios are most correlated with ADAP.

The table below shows ADAP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.016 1 -0.462
2021-06-30 0.014 1 -0.414
2021-03-31 0.008 1 -0.374
2020-12-31 0.009 1 -0.397
2020-09-30 0.009 1 -0.466
2020-06-30 0.008 1 -0.617

ADAP Stock Price Chart Interactive Chart >

Price chart for ADAP

ADAP Price/Volume Stats

Current price $2.17 52-week high $4.28
Prev. close $2.19 52-week low $1.01
Day low $2.15 Volume 356,700
Day high $2.38 Avg. volume 610,849
50-day MA $1.59 Dividend yield N/A
200-day MA $1.83 Market Cap 355.51M

Adaptimmune Therapeutics plc (ADAP) Company Bio


Adaptimmune Therapeutics plc is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. The company was founded in 2014 and is based in Abingdon, the United Kingdom.


ADAP Latest News Stream


Event/Time News Detail
Loading, please wait...

ADAP Latest Social Stream


Loading social stream, please wait...

View Full ADAP Social Stream

Latest ADAP News From Around the Web

Below are the latest news stories about ADAPTIMMUNE THERAPEUTICS PLC that investors may wish to consider to help them evaluate ADAP as an investment opportunity.

Adaptimmune Therapeutics (ADAP) Gets a Buy from Mizuho Securities

E ratio of -2.15.

Austin Angelo on TipRanks | November 18, 2022

Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent

- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after a single dose of afami-cel -- Overall response rate in synovial sarcoma of 39% by independent review -consistent with previous data - -Median duration of response of 50 weeks, consistent with previous data -- Afami-cel drives tumor infiltration of activated and proliferative cytotoxic ("killer") T-cells into tumors - which likely contributes to ant

Yahoo | November 18, 2022

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Genmab (GMAB) and Adaptimmune Therapeutics (ADAP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA – Research Report), Genmab (GMAB – Research Report) and Adaptimmune Therapeutics (ADAP – Research Report). Moderna (MRNA) Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna today and set a price target of $506.00. The company's shares closed last Monday at $179.50. According to TipRanks.

Christine Brown on TipRanks | November 14, 2022

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Celebrations may be in order for Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders, with the analysts...

Yahoo | November 13, 2022

Lab notes: Adaptimmune to reduce workforce; NRx completes $11M debt financing

This week's Lab Notes has items on a cell therapy developer joining the list of life sciences companies making staff reductions, a multimillion-dollar debt financing deal, an update on a company's efforts to develop biosimilar products and more. Here's the roundup: AdaptImmune (NASDAQ: ADAP) The cell therapy developer with operations in Philadelphia and Oxford, England, said this week it is cutting its workforce by 25% to 30% and narrowing its research focus to conserve cash. The company also said it is prioritizing its two lead T-cell therapy programs targeting solid tumors.

Yahoo | November 11, 2022

Read More 'ADAP' Stories Here

ADAP Price Returns

1-mo 49.66%
3-mo 7.43%
6-mo 29.94%
1-year -41.35%
3-year 82.35%
5-year -73.21%
YTD -42.13%
2021 -30.43%
2020 349.17%
2019 -79.13%
2018 -13.92%
2017 64.94%

Continue Researching ADAP

Here are a few links from around the web to help you further your research on Adaptimmune Therapeutics PLC's stock as an investment opportunity:

Adaptimmune Therapeutics PLC (ADAP) Stock Price | Nasdaq
Adaptimmune Therapeutics PLC (ADAP) Stock Quote, History and News - Yahoo Finance
Adaptimmune Therapeutics PLC (ADAP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8241 seconds.